Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo

Hepatocellular carcinoma (HCC) is the sixth most frequent malignant tumor with poor prognosis, and its clinical therapeutic outcome is poor. Volasertib, a potent small molecular inhibitor of polo-like kinase 1 (PLK1), is currently tested for treatment of multiple cancers in the clinical trials. Howe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Cancer Res
Main Authors: Zheng, Di-Wei, Xue, You-Qiu, Li, Yong, Di, Jin-Ming, Qiu, Jian-Ge, Zhang, Wen-Ji, Jiang, Qi-Wei, Yang, Yang, Chen, Yao, Wei, Meng-Ning, Huang, Jia-Rong, Wang, Kun, Wei, Xing, Shi, Zhi
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5126267/
https://ncbi.nlm.nih.gov/pubmed/27904765
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados